Related Experiment Video
Updated: Jan 26, 2026
10:37
Perturbations of Circulating miRNAs in Irritable Bowel Syndrome Detected Using a Multiplexed High-throughput Gene Expression Platform
Published on: November 30, 2016
8.7K
Should We Use Tegaserod for Irritable Bowel Syndrome?
Thomas A Marciniak1, Victor Serebruany2
1Bethany Beach, DE.
American Journal of Therapeutics
|April 5, 2019
Summary
Uncertainties about tegaserod metabolism and incomplete cardiovascular risk data hinder its assessment. Further investigation into pentylaminoguanidine and complete clinical trial follow-up are crucial for evaluating this serotonin (5-HT4) agonist.
Area of Science:
- Pharmacology and clinical trial analysis of drug safety and efficacy.
- Regulatory science and post-market surveillance.
Background:
- Tegaserod, a serotonin (5-HT4) agonist, was withdrawn in 2007 due to cardiovascular concerns.
- Resubmitted in 2018 for restricted use, critical pharmacology and clinical trial data remain unaddressed.
Discussion:
- The metabolic fate and effects of the pentylaminoguanidine moiety of tegaserod are unknown.
- Incomplete subject follow-up and cardiovascular event capture in trials prevent accurate risk estimation.
- Potential receptor interactions suggest possible cardiovascular effects.
Key Insights:
- Incomplete tegaserod metabolism data, particularly regarding pentylaminoguanidine, obscure its safety and efficacy profile.
- Clinical trial data suggest a low but definite cardiovascular risk, yet are insufficient for precise quantification.
- Uncertainty in metabolism and cardiovascular risk may limit clinical adoption.
Outlook:
- Aggressive pursuit of subtle cardiovascular toxicity signals is essential in drug development.
- Complete case follow-up and robust cardiovascular event capture are critical for future assessments.
- Further research into tegaserod's metabolites and cardiovascular effects is warranted.
Related Concept Videos
01:17Irritable Bowel Syndrome I: Introduction
954
Irritable Bowel Syndrome (IBS) is characterized by functional disturbances in the gastrointestinal system, presenting a cluster of symptoms without evident structural or biochemical abnormalities. It primarily affects the large intestine and may cause abdominal pain, bloating, excessive gas, diarrhea, constipation, or both.
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
954
01:30Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation
751
Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation
Irritable Bowel Syndrome (IBS) is classified into subtypes based on the predominant bowel habits as determined by the Bristol Stool Form Scale (BSFS). The subtypes are:
Irritable Bowel Syndrome (IBS) is classified into subtypes based on the predominant bowel habits as determined by the Bristol Stool Form Scale (BSFS). The subtypes are:
751
01:30Irritable Bowel Syndrome III: Medical and Nursing Management
663
Managing Irritable Bowel Syndrome (IBS) involves a multifaceted approach, including lifestyle modifications, dietary changes, and medication.
663
01:17Chronic Bowel Disorders: Introduction
769
Chronic bowel diseases are a group of long-term conditions affecting the digestive tract, characterized by inflammation and damage to the gut lining. These conditions primarily include irritable bowel syndrome and inflammatory bowel disease.
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
769
01:30Inflammatory Bowel Disease II: Crohn's Disease
1.0K
Introduction
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
1.0K
01:27Inflammatory Bowel Disease I: Ulcerative Colitis
953
Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
953